Company: HCTI
Filing Date: 2025-03-17
Form Type: DEF 14C
Source: 0001213900-25-024319
Chunk: 1

Company: Healthcare Triangle, Inc.
Filing Date: 2025-03-17
Form: DEF 14C
Chunk 1
---
24, 2025 (the “ Record Date”). The purpose of this Information Statement is to notify holders of our Common Stock and Series A Preferred Stock as of the Record Date (the “ Stockholders”) that the Company’s Board of Directors (the “ Board”) and the holders of a majority of our outstanding voting capital stock (the “ Majority Stockholders”) approved of the following corporate actions (the “ Corporate Actions”): •amendment of our certificate of incorporation, as amended (“ Certificate of Incorporation”), to effect a reverse stock split of our Common Stock at a reverse stock split ratio ranging from 1:2 to 1:250 inclusive, as determined by our Board in its sole discretion (the “ Approval of Certificate of Incorporation Amendment for Split”); and •amendment of our Certificate of Incorporation to increase the total number of authorized shares (the “ Increase in Authorized Shares”) from one hundred ten million (110,000,000) shares to two billion ten million (2,010,000,000) shares, consisting of two billion (2,000,000,000) shares of Common Stock and ten million (10,000,000) shares of preferred stock (the “ Approval of Certificate of Incorporation Amendment for Increase in Authorized Shares”); and •authorization, for purposes of complying with Nasdaq listing rule 5635(d), of the issuance of Warrants (as defined below), shares of Common Stock underlying the Warrants and certain provisions of the Warrants, issued in connection with an offering and sale of securities of the Company that was consummated on February27, 2025 (the “ Issuance Approval”) On the Record Date, the Majority Stockholders approved the Corporate Actions by written consent in place of a stockholders’ meeting as permitted under the Delaware General Company Law (the “ DGCL”) and our Bylaws. Accordingly, your consent is not required and is not being solicited in connection with the approval of the Corporate Actions. Our Board is not soliciting your proxy or consent in connection with the Corporate Actions. You are urged to read this Information Statement carefully and in its entirety for a description of the Corporate Actions approved by the Board and the Majority Stockholders. Stockholders who were not afforded an opportunity to consent or otherwise vote with respect to the Corporate Actions taken have no right under the DGCL or our Bylaws to dissent or require a vote of all Stockholders. Pursuant to Rule 14c -2under the Exchange Act, the Corporate Actions will not become effective before